Expert Highlights Applications of Proton Therapy in Radiation Oncology

Commentary
Video

The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.

Administering proton therapy to pediatric populations with cancer may serve as a “great application” that helps patients avoid developing mutations and second cancers, says Timothy Chen, MD.

Chen, a board-certified radiation oncologist and medical director of the Central Nervous System Program at Jersey Shore University Medical Center and the director of Proton Therapy in the Department of Radiation Oncology at Hackensack Meridian Health, spoke with CancerNetwork® about the potential applications of proton therapy and benefits this modality may offer compared with standard radiation.

In addition to the potential utility of proton therapy among pediatric populations, Chen highlighted how this technique may demonstrate more precision than others based on what he described as a “depth charge.” For example, it may be possible to administer proton therapy to breast tumors while sparing the lungs from receiving any excess radiation.

Transcript:

Proton therapy is type of radiation but with a different particle hitting the target. If you think about conventional radiation like a pistol, proton [therapy] is like a cannon. It also has a great purpose with what’s called a depth charge. We can set a cannon to be explored at a certain depth. The conventional radiation comes and goes while passing through the structure. With proton therapy, we can say where I want to go and stop right there. With that, there are great applications.

No. 1 is in pediatric [patients with] cancer. Because a child is still growing, the conventional radiation can create mutations, and they could eventually develop a second cancer in their later life. Proton therapy is a particularly great design for pediatric patients [with] cancer; their chance of getting a mutation or a second cancer is smaller.

The second thing is about the depth charge. Because we can set the characteristic of this beam, we can treat quite a large area that’s not accessible with conventional radiation. For example, in breast cancer, the breast sits on top of the chest wall, and as we breathe, the lungs get in [the way and receive] the radiation. But because we can set the depth [with proton therapy], you can confine radiation to the breasts and not touch the lungs.

Related Videos
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Related Content